Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.50
Ask: 41.50
Change: 1.00 (2.50%)
Spread: 1.00 (2.469%)
Open: 40.00
High: 41.00
Low: 40.00
Prev. Close: 40.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

Tue, 05th Mar 2024 17:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

STV Group PLC - Glasgow-based broadcaster - Revenue grows 22% to GBP168.4 million in 2023 from GBP137.8 million a year prior. Total advertising revenue drops 12% to GBP97.3 million from GBP110.0 million. Adjusted pretax profit was GBP9.5 million for the year, down from GBP24.1 million in 2022. STV's dividend was flat for the year at 11.3p per share, after a final dividend of 7.4p. STV has secured GBP87 million in future revenue as at March, GBP30 million a head of the same time a year ago, and the company is encouraged by the "resilience" shown by the advertising market in the year so far. Chief Executive Officer Simon Pitts says: "Our overall financial performance was impacted by weak linear advertising and cost inflation, as expected and related to the challenging UK macro environment, although the start of 2024 has been more encouraging."

----------

Avacta Group PLC- Wetherby, England-based life sciences company specialising in oncology treatments - Set to issue 10.9 million new shares at a price of 50p each following its February retail offer. This remains subject to shareholder approval at the company's annual general meeting on March 18. The REX offer received total applications in excess of the GBP6.8 million limit. The company decided to limit the offer to existing Avacta retail shareholders, and expects a total of GBP5.4 million to be raised from the offer. The company says the proceeds will be used to support the continued clinical development of AVA6000, the company's signature treatment capable of targeting a chemotherapy to the tumour while sparing healthy tissue.

----------

Argo Blockchain PLC - London-based cryptocurrency miner - Enters into agreement for sale of Mirabel, Quebec data centre for a total consideration of USD6.1 million. The proceeds from the sale will be used to repay the facility's outstanding mortgage in full, and the remainder used to pay debts owned to Galaxy Digital Holdings Ltd, an asset manager and trade advisor specialising in digital assets. As of February 29, the Galaxy debt stands at USD14.0 million. The company is in the process of moving mining machines out of the Mirabel facility, and expects the transaction to close by the end of March.

----------

Harland & Wolff Group Holdings PLC - London-based fabrication company, which serves the maritime and offshore industries - Says it has been awarded preferred bidder status for the Falkland Islands Port Replacement Project by the Falkland Islands Government. H&W believes this contract could generate total revenues between GBP100 and GBP120 million over a two-year period, with works on the project expected to commence this year.

----------

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell-therapy company - Updates annual guidance, expecting 2024 revenue of around GBP126 million to GBP134 million. Guidance for the 2023 full-year remains unchanged, with group revenue expected to be around GBP90 million. The group is expecting a loss before interest, tax, depreciation and amortisation for 2023, but is targeting break-even operating Ebitda by the end of 2024.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
10 Jun 2019 10:51

Avacta Selects Candidate For First Human Trials Of Affimer Platform

LONDON (Alliance News) - Avacta Group PLC on Monday said it has selected a clinical development candidate AVA004 for first-time-in-human clinical trials of its Affimer platform.Affimer an a

Read more
3 Jun 2019 10:20

Avacta To Submit Application For TMAC Linker Testing In Tumours Study

LONDON (Alliance News) - Avacta Group PLC on Monday said it is planning to submit an application to test its TMAC linker in patients with selected solid tumours in early 2020.The company, a

Read more
9 Apr 2019 12:11

Avacta falls as stuttering revenues exacerbate losses

(Sharecast News) - Avacta Group's shares slid on Tuesday as interim revenues dropped on the back of a lower contribution from the life sciences division, which resulted in wider losses.

Read more
9 Apr 2019 10:37

Avacta shares fall as interim revenues slide

(Sharecast News) - Biotherapeutics and research reagents developer Avacta Group reported a fall in half-year revenues to £1.0m on Tuesday, from £1.5m a year earlier.

Read more
9 Apr 2019 09:49

Avacta Shares Fall On Widened Interim Loss, Lower Revenue

LONDON (Alliance News) - Avacta Group PLC on Tuesday reported a widened first half loss mainly due to lower income contribution from life sciences unit.The stock was trading 8.5% lower on a

Read more
28 Jan 2019 12:01

Avacta Hires IP Group Unit Boss Sam Williams As Non-Executive Director

LONDON (Alliance News) - Avacta Group PLC on Monday said it has appointed Sam Williams as a non-executive director with immediate effect.The biotechnology company said Williams is currently

Read more
21 Jan 2019 12:14

Avacta Group makes solid development progress

(Sharecast News) - Biotherapeutics developer Avacta Group updated the market on its trading on Monday, as investors gathered for its annual general meeting.

Read more
3 Jan 2019 11:34

IP Group Builds Over 17% Holding In Biotechnology Firm Avacta (ALLISS)

LONDON (Alliance News) - Avacta Group PLC on Thursday said IP Group PLC now holds 17.2% stake in the biotechnology company following a transaction on December 18.Prior to that, IP holding

Read more
12 Dec 2018 11:14

Avacta Group Appoints Roche's Jose Saro As Chief Medical Officer

LONDON (Alliance News) - Reagents developer Avacta Group PLC on Wednesday appointed Jose Saro as chief medical officer to lead the firm's therapeutic development strategy.Saro brings 20

Read more
12 Dec 2018 09:45

Avacta Group picks up Jose Saro as chief medical officer

(Sharecast News) - Biotherapeutic development company Avacta Group announced on Wednesday that Dr Jose Saro has been appointed as its chief medical officer, to lead its therapeutic development strategy and drive the in-house programmes into the clinic.

Read more
10 Dec 2018 08:52

IP Group Investee Teams With LG Chem To Develop Affimer Drug Candidate

LONDON (Alliance News) - IP Group PLC on Monday said its portfolio company Avacta Group PLC signed a development & license deal with LG Chem Life Sciences.IP Group currently holds a in

Read more
10 Oct 2018 16:33

Avacta 'delighted' at license agreement with longtime collaborator

(Sharecast News) - Avacta Group agreed a commercial license with New England Biolabs (NEB) to commercialise a science and research assay project using its Affimer technology on Wednesday.

Read more
2 Oct 2018 15:23

Avacta hails progress on in-house and third-party programmes

(Sharecast News) - Avacta Group posted a slightly wider full-year loss on Wednesday even as it highlighted progress both with its in-house programmes and third parties.

Read more
2 Oct 2018 09:42

Avacta Annual Revenue Increases But Loss Widens On Higher Expenses

LONDON (Alliance News) - Avacta Group PLC on Tuesday said its loss widened in its recently-ended financial year on higher costs, as it continues to progress Affimer.The reagents developer a

Read more
23 Aug 2018 17:38

FIL Reduces Avacta Stake To Below 5% Threshold After Deal (ALLISS)

LONDON (Alliance News) - Avacta Group PLC said Thursday that FIL Ltd decreased its stake in the biotechnology company to below 5% after a transaction on Tuesday.FIL lowered its holding to a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.